Company Overview and News
New Delhi: Finance minister Arun Jaitley has dismissed opposition Congress chief Rahul Gandhi’s accusations that the Rafale fighter jet deal with France has resulted in an advantage between ₹38,000 crore and ₹130,000 crore for an Indian business house as a falsehood.
ORLANDO, Fla. (Reuters) - French planemaker Dassault Aviation (AVMD.PA) will nudge up production rates on certain business jet models, including its Falcoln 8x and 2000 jets, Chief Executive Eric Trappier said on Monday, a sign of broader industry demand for corporate aircraft.
Disgruntled BJP leader Shatrughan Sinha criticised the BJP government at the Centre over the Rafale deal. He said a French publication had quoted former French president Francois Hollande as saying that the Indian government had proposed Reliance Defence as a partner for the French aerospace major Dassault Aviation for the deal.
Continuing with its campaign against the government over the Rafale deal, the Congress Sunday claimed that Prime Minister Narendra Modi was directly involved in it, adding that he had much to hide about it.
Mumbai: Calling the Rafale deal the “largest defence scam” in the country, Advocate Prashant Bhushan said Saturday that the he hoped that the Central Bureau of Investigation (CBI) will act upon the complaint made by him and two others against Prime Minister Narendra Modi and others in the case, and register a Preliminary Enquiry, or an FIR. Bhushan said that if the CBI failed to follow due process, he will then take the case to court.
Congress president Rahul Gandhi today described HAL as a “strategic asset” in aerospace, saying the country owed a debt to it, as he stepped up his campaign against the Modi government over the Rafale fighter jet deal.
Bengaluru: Congress president Rahul Gandhi today described HAL as a “strategic asset” in aerospace, saying the country owed a debt to it, as he stepped up his campaign against the Modi government over the Rafale fighter jet deal. Reaching out to present and former employees of the defence PSU at an interaction with them here, Gandhi said, work done by HAL for the country was tremendous and the country owed debt to it for “protecting us” and creating a scientific vision.
Paris/New Delhi: In France, on a three-day visit, Defence Minister Nirmala Sitharaman has refuted Congress allegations that she has gone on a cover-up operation and insisted that the government had no part in the selection of Anil Ambani’s Reliance Defence as a joint venture partner in the Rafale deal.
NEW DELHI/PARIS Oct 11 (Reuters) - Dassault Aviation said it picked India’s Reliance Defence as a partner for a big military combat deal on its own, countering a French online media report that said the Indian government insisted on the firm as a condition of the contract.
New Delhi: Firing a fresh salvo at Prime Minister Narendra Modi over the Rafale deal, Congress president Rahul Gandhi alleged on Thursday that he was a “corrupt man” who helped Anil Ambani pocket Rs 30,000 crore in the purchase of the fighter aircraft. Gandhi demanded an investigation against the prime minister.
Paris: Dassault clarified on Wednesday that it had “freely chosen” India’s Reliance Group for a partnership to set up joint-venture Dassault Reliance Aerospace Ltd (DRAL) to manufacture parts for Rafale aircraft and Falcon 2000 business jets.
Dassault Aviation clarified on Wednesday that it had “freely chosen” India’s Reliance Group for a partnership to set up joint-venture Dassault Reliance Aerospace Ltd (DRAL) to manufacture parts for Rafale aircraft and Falcon 2000 business jets. In a statement, Dassault further confirmed that “it has sold 36 Rafale aircraft to India within the framework of the September 2016 Inter-Government Agreement between France and India”.
New Delhi: The Congress on Wednesday accused the Modi government of “manipulating” the process of Rafale fighter jet agreement by “punishing” bureaucrats who raised objections to the deal and rewarding “obliging officials”, as Rahul Gandhi raised questions on Defence Minister Nirmala Sitharaman’s France visit.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EPA:AM / DASSAULT AVIATION on message board site Silicon Investor.